BioStock: Evaxion enrols first patient in phase IIb melanoma study

Evaxion Biotech’s lead immunotherapy candidate, EVX-01, developed through one of the company’s AI platforms, has entered clinical development phase IIb in metastatic melanoma patients. With the announcement of the first patient enrolled in the study, BioStock spoke with Evaxion’s CMO Erik Heegaard to learn more about this important milestone.

Read the interview with Erik Heegaard at biostock.se:

https://www.biostock.se/en/2022/10/evaxion-enrols-first-patient-in-phase-iib-melanoma-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/